問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

更新時間:2024-02-21

陳寧君
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2026-04-20 - 2034-12-31

Phase II/III

Not yet recruiting
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in participants with 1L follicular lymphoma
  • Condition/Disease

    Follicular Lymphoma

  • Test Drug

    MK-1045 Rituximab

Participate Sites
2Sites

Not yet recruiting2Sites

2023-06-01 - 2028-03-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-10-15 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2023-11-01 - 2031-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-05-01 - 2028-12-22

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-06-03 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-20 - 2034-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites